Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris
Status:
Completed
Trial end date:
2019-04-22
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study,
designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the
marketed product Clindamycin 1% gel (Greenstone LLC) in the treatment of acne vulgaris.